The drug regulator said the company made claims for the drug product for which it had not obtained approval from the Central Licensing Authority, thereby violating provisions under the New Drugs and Clinical Trial Rules, 2019.
DCGI suspends ENTOD’s PresVu eye drops licence after misleading marketing claims, company to challenge order in court
